Skip to main content

Table 7 Main and secondary outcomes for medicine groups at twelve week follow up

From: Management of irritable bowel syndrome in primary care: the results of an exploratory randomised controlled trial of mebeverine, methylcellulose, placebo and a self-management website

Variable

Mebeverine

Methylcellulose

Placebo

Significance

IBS-SSS total mean (n = 123)

203.1(181.3- 223.0)

205.4 (185.3 -225.5)

210.9 (191.1 - 230.7)

p = 0.865

IBS-QOL score (n = 123)

68.9 (64.1 – 73.6)

66.3 (61.9 – 70.8)

70.2 (65.9 – 74.6)

P = 0.453

HADS score for anxiety (n = 114)

8.2 (7.3 – 9.1)

8.7 (7.9- 9.6)

9.0 (8.2 -9.8)

p = 0.422

HADS score for depression (n = 114) (%)

   

P = 0.655

Normal (0–7)

25 (78.1)

35 (89.7)

33 (76.7)

 

Mild (8–10)

5 (15.6)

2 (5.1)

7 (16.3)

 

Moderate or Severe (11–21)

2 (6.3)

2 (5.1)

3 (7.0)

 

Enablement score (n = 113)

   

P = 0.231

0

6 (19.4)

14 (35.9)

12 (27.9)

 

1-2

5 (16.1)

6 (15.4)

5 (11.6)

 

3-5

9 (29.0)

11 (28.2)

15 (34.9)

 

6-12

11 (35.5)

8 (20.5)

11(25.6)

 

SGA (%)

    

Responders

16 (57.1)

17 (43.6)

19 (44.2)

P = 0.538

Non responders

12 (42.9)

22 (56.4)

24 (55.8)

 
  1. ANCOVA for IBS SSS, IBS-QOL and HADs Anxiety, Mean (95% CI). Ordinal Regression for HADs Depression, Enablement and SGA (n (%).